1pm PT (4pm ET, 9pm GMT)
The global diabetes epidemic is presenting enormous challenges for health care models around the world. While much of the focus remains on tight glycemic control, increased attention is being paid to the associated problems of hypoglycemia in these patients. Xeris is addressing both of these issues with the development of a stable, non-aqueous, injectable glucagon. Xeris has already developed a room-temperature-stable formulation which is being leveraged for multiple opportunities ranging from rescue pens for the treatment of severe hypoglycemia to pump-based formulations for use in an artificial pancreas.